Family Office Briefing on research bySavills·Nov 6, 2024
The Life Sciences Tenant Q3 2024
Life sciences market shows signs of developer caution in Q3 2024 — family offices should consider co-GP opportunities with disciplined operators.
Life ScienceQ3 2024
Key Metrics
| Metric | Value |
|---|---|
| Venture Capital Funding Increase | 20% |
| M&A Activity Surge | 92.6% |
| Decrease in Life Sciences M&A Deals | 11.0% |
Metrics extracted from the source report and independently fact-checked. Method →
Full report
Savills
Building a thesis around Life Science? Share it confidentially with the Thesis Exchange — we pair you anonymously with family offices running adjacent life science strategies.
Peer Network · By Invitation
The Thesis Exchange
Share an investment thesis in confidence. We pair you anonymously with up to two other family offices running adjacent strategies. Reviewed by Gallium's editorial team. No vendor pitch.